Researchers identified secondary or incidental findings in just over 3 percent of the nearly 22,000 EMERGE III participants, who were profiled with a 109-gene panel.
In PLOS this week: genomic analysis of multidrug-resistant Mycobacterium tuberculosis strains from Colombia, inflammatory response signatures in cancer, and more.
In PNAS this week: comparative genomic analysis to find Pseudomonas aeruginosa virulence genes, "anti-CRISPR" proteins in Staphylococcus aureus, and more.
Although polygenic risk scores for coronary artery disease can slightly improve standard risk assessment tools, the predicted clinical impact remains small.
